**Supplement**

**Supplement Table 1. Comparison of the medication usage according to the LVEF quartiles**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 　 | Q1（n=30）LVEF＞63% | Q2（n=30）61%＜LVEF≤63% | Q3（n=30）57%＜LVEF≤61% | Q4（n=32）LVEF≤57% | *p* |
| Sulfonylureas (%) | 16.7% | 26.7% | 10.0% | 15.6% | 0.386 |
| Metformin (%) | 80.0% | 76.7% | 66.7% | 68.8% | 0.604 |
| GLP-1RA (%) | 0.0% | 10.0% | 6.7% | 15.6% | 0.155 |
| DPP-4i (%) | 26.7% | 10.0% | 16.7% | 15.6% | 0.386 |
| SGLT2i (%) | 43.3% | 40.0% | 33.3% | 43.8% | 0.830 |
| Insulin (%) | 53.3% | 36.7% | 46.7% | 40.6% | 0.584 |
| Thiazolidinediones (%) | 6.7% | 13.3% | 10.0% | 6.3% | 0.749 |
| α-glucosidase inhibitor (%) | 13.3% | 30.0% | 23.3% | 25.0% | 0.477 |
| Antihypertensive medications（%） | 43.3% | 33.3% | 40% | 43.8% | 0.800 |

Categorical values are shown as frequency. GLP-1RA, glucagon-like peptide-1 receptor agonist; DPP-4i, dipeptidyl peptidase-IV inhibitor; SGLT2i, sodium-dependent glucose transporter 2 inhibitor.

**Supplement Table 2. Comparison of baseline characteristics according to LVEF quartiles**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Q1（n=30）LVEF＞63% | Q2（n=30）61%＜LVEF≤63% | Q3（n=30）57%＜LVEF≤61% | Q4（n=32）LVEF≤57% | *p* |
| DBP (mmHg) | 75.50±8.12 | 71.77±10.83 | 77.53±10.41 | 76.56±12.35 | 0.170 |
| SBP (mmHg) | 125.46±17.12 | 119.77±17.16 | 124.20±16.10 | 123.53±17.61 | 0.609 |
| HOMA-IR | 16.98±19.55 | 19.58±23.53 | 19.53±19.23 | 19.53±15.25 | 0.942 |
| PLT（10^9/L） | 233.90±55.19 | 223.30±65.93 | 230.52±70.03 | 227.63±82.02 | 0.945 |
| ALT（U/L） | 20.75±15.40 | 25.99±23.06 | 25.94±18.20 | 24.13±15.44 | 0.661 |
| AST（U/L） | 17.03±5.31 | 20.10±13.45 | 19.27±9.56 | 19.58±7.70 | 0.605 |
| ALP（U/L） | 72.10±19.37 | 73.10±16.42 | 76.40±25.99 | 69.22±21.26 | 0.610 |
| γ-GT（U/L） | 38.87±62.38 | 28.38±23.63 | 39.43±55.41 | 36.38±26.24 | 0.772 |
| ALB（g/L） | 42.10±3.37 | 42.79±3.28 | 42.46±4.23 | 43.34±3.68 | 0.594 |
| BUN (mmol/L) | 5.32±1.92 | 5.85±2.16 | 5.25±1.32 | 5.20±1.10 | 0.417 |
| Cr (umol/L) | 64.39±22.27 | 63.98±24.26 | 67.79±15.02 | 65.02±15.53 | 0.876 |
| fT3 (pmol/L) | 4.32±0.83 | 4.60±0.69 | 4.51±0.50 | 4.60±0.89 | 0.409 |
| fT4 (pmol/L) | 20.64±22.10 | 16.77±3.39 | 17.10±2.67 | 16.40±2.16 | 0.449 |
| sTSH (uIU/ml) | 1.90±1.30 | 1.58±0.80 | 2.13±1.68 | 1.92±1.63 | 0.527 |
| UA/CR（mg/g） | 23.69±41.89 | 21.77±25.07 | 38.50±73.18 | 41.84±80.41 | 0.451 |
| HBP(%) | 46.7% | 33.3% | 40.0% | 46.9% | 0.670 |
| HPL(%) | 26.7% | 33.3% | 20.0% | 15.6% | 0.382 |

Continuous values consistent with normal distribution are shown as mean ± standard deviation. Categorical values are shown as frequency. DBP, diastolic blood pressure; SBP, systolic blood pressure; PLT, platelet count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ- Glutamyl transpeptidase; ALB, serum albumin; BUN, serum urea nitrogen; Cr, serum creatinine; UA/CR, urine microalbumin/creatinine ratio;fT3, free triiodothyronine;fT4, free thyroxine; sTSH, high-sensitivity thyroid stimulating hormone; HBP, High blood pressure; HPL, High blood lipids.